

## ASX Release

---

# SENIOR CELL AND GENE THERAPY MANUFACTURING EXPERT TO JOIN SUDA

- Dr Sandhya Buchanan joins SUDA to lead the technology transfer, manufacturing, and quality efforts for its newly acquired invariant Natural Killer T (iNKT) cell therapy platform.
- Dr Buchanan has more than 20 years' experience working in cell & gene therapy and vaccine development for organisations including Novartis, FujiFilm Diosynth, Torque Biotherapeutics (now Repertoire Immune Medicines) and Atara Biotherapeutics.
- Dr Buchanan was previously a Senior Director of Viral Vector Development at Atara Biotherapeutics, a biotechnology company pioneering off-the-shelf cell therapies for the treatment of cancer and autoimmune disease.

**PERTH, AUSTRALIA – 2 Aug 2021:** SUDA Pharmaceuticals Ltd (ASX: SUD), is pleased to announce the appointment of Dr Sandhya Buchanan as its VP of Manufacturing and Quality for its newly acquired iNKT cell therapy platform. SUDA recently announced that it secured the exclusive, global licence to the novel platform developed at Imperial College London. Dr Buchanan's role will encompass leading the technology transfer, manufacturing, and quality aspects for production of the cell therapy for clinical development stages.

Dr Buchanan joins SUDA from Atara Biotherapeutics, a biotechnology company pioneering off-the-shelf cell therapies for treating cancer and autoimmune disease.

During her time at Atara Biotherapeutics, Dr Buchanan served as the chemistry manufacturing and control technical lead for autologous CAR-T programs and head of Viral Vector Development; managing both internal and external collaborations. Prior to Atara Biotherapeutics, Dr Buchanan held senior roles at Torque Therapeutics (now Repertoire Immune Medicines), FujiFilm Diosynth Biotechnologies, Penn Medicine, a world-renowned academic medical center in Philadelphia, and Novartis.

Dr Buchanan has more than 20 years' experience working in cell & gene therapy and vaccine development. Dr Buchanan has a PhD in Pharmaceutical Sciences from the University of Colorado Health Sciences Center and has co-authored a number of peer reviewed scientific articles and patents.

SUDA's CEO and MD, Dr Michael Baker, commented: "We are delighted to have someone of Dr Buchanan's calibre joining the team at SUDA. Dr Buchanan's extensive experience in the production of cell and gene therapies will be important factor as we advance our iNKT cell therapy into and through the clinical stages of development."

*Dr Michael Baker, CEO and Managing Director of Suda Pharmaceuticals Ltd has authorised the release of this announcement to the market.*

For and on behalf of the Board and for further information please contact:

**Dr Michael Baker**

**Chief Executive Officer & Managing Director**

**SUDA Pharmaceuticals Ltd**

Tel +61 (0) 403 468 187

mbaker@sudapharma.com

## **NOTES TO EDITORS:**

### **About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a biotechnology company focused on developing therapies to treat human disease. SUDA's two focus areas are oncology and conditions that impact the central nervous system. SUDA is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers. The Company is also developing low-risk oral sprays to reformulate existing pharmaceuticals. The potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes an oral spray for the platelet-lowering drug anagrelide to treat metastatic disease in the background of high platelets, and ZolpiMist™, a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. ZolpiMist is approved by the FDA and the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

For more information, visit [www.sudapharma.com](http://www.sudapharma.com)

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding actions of third parties and financial terms. These factors and assumptions are based upon currently available information and the forward-looking statements contained herein speak only as of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include, but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.